Marker Therapeutics (MRKR)

• Market cap: $12.3M
• 1 day: 6.48%
• 5 days: 10.58%
• 1 month: -10.16%
• 3 months: -53.25%
• 6 months: -64.62%
• Year to date: -63.84%
• 1 year: -73.32%
• 5 years: -94.39%
• 10 years: -97.90%
• Sector: Healthcare
• Industry: Biotechnology

About: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Employees: 5

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

772% more capital invested

Capital invested by funds: $5.67M [Q3] → $49.5M (+$43.8M) [Q4]

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

19.15% more ownership

Funds ownership: 22.54% [Q3] → 41.7% (+19.15%) [Q4]

18% more funds holding

Funds holding: 28 [Q3] → 33 (+5) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 596% upside
• Avg. target: $10.25 791% upside
• High target: $12.50 987% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

WBB Securities Steve Brozak 0% 1-year accuracy 0 / 1 met price target	987% upside $12.50	Strong Buy Reiterated	1 Apr 2025
Canaccord Genuity John Newman 12% 1-year accuracy 3 / 26 met price target	596% upside $8	Buy Initiated	5 Mar 2025